Literature DB >> 7598734

The proton pump inhibitor, E3810, binds to the N-terminal half of the alpha-subunit of gastric H+,K(+)-ATPase.

M Morii1, K Hamatani, N Takeguchi.   

Abstract

E3810 (2-([4-(3-methoxypropoxy)-3-methylpyridine-2-yl]methylsulphinyl )- 1H-benzimidazole sodium salt), an inhibitor of gastric proton pump (gastric H+,K(+)-ATPase), is activated in a luminal acidic environment of gastric glands and binds to a Cys residue of H+,K(+)-ATPase on its luminal side. It was found that bound E3810 is transformed into a strongly fluorescent compound by UV-light irradiation (excitation wavelength = 335 nm, emission wavelength = 470 nm). The location of Cys residue bound with E3810 in the alpha-subunit of hog gastric H+,K(+)-ATPase was estimated from the fluorescence labelling and limited tryptic digestion of the enzyme. Tryptic digestion in the presence of Mg-ATP produces N-terminal 67 kDa subfragment which contains the phosphorylation and fluorescein 5'-isothiocyanate binding sites and C-terminal 35 kDa subfragment. Trypsin digestion in the presence of KCl produces N-terminal 42 kDa and C-terminal 56 kDa subfragments. E3810 was found to bind to both N-terminal but not to any of two C-terminal subfragments. Taking the amino acid sequence and topology of this ATPase as well as the fact that the ratio of specific binding sites per alpha-subunit is one into consideration, the possibility that E3810 specifically binds to Cys322 residue of hog gastric H+,K(+)-ATPase is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7598734     DOI: 10.1016/0006-2952(95)00090-m

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Bioequivalence evaluation of two rabeprazole enteric coated formulations in healthy Chinese volunteers.

Authors:  Jun Chen; Wen Ming Jiang; Xiao Ling Gao; Xinguo Jiang; Qi Zhi Zhang; Zhao Hua Zheng
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Apr-Jun       Impact factor: 2.441

2.  Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve.

Authors:  Takenori Niioka; Tsukasa Uno; Norio Yasui-Furukori; Mikiko Shimizu; Kazunobu Sugawara; Tomonori Tateishi
Journal:  Eur J Clin Pharmacol       Date:  2006-08-17       Impact factor: 2.953

3.  Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.

Authors:  Tomohiko Shimatani; Masaki Inoue; Tomoko Kuroiwa; Jing Xu; Susumu Tazuma; Yoko Horikawa; Masuo Nakamura
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

Review 4.  Rabeprazole.

Authors:  A Prakash; D Faulds
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

5.  Rabeprazole controls GERD symptoms in a patient for whom treatment with lansoprazole failed: first report of "cluster GERD.".

Authors:  David S Oh; Gordon V Ohning; Joseph R Pisegna
Journal:  Dig Dis Sci       Date:  2005-05       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.